Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]
about
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapyVaricella-zoster virusAbsence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected miceFamciclovir for treatment of herpesvirus infectionsMode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virusCross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virusComparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression modelIn vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virusEvaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpesPreclinical aspects of lamivudine and famciclovir against hepatitis B virus.Determination of penciclovir in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study.Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbitsEmerging drugs for varicella-zoster virus infections.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management9-[4-Hydr-oxy-3-(hydroxy-meth-yl)but-yl]guanine monohydrateReview of antiviral therapy for herpes labialis, genital herpes and herpes zoster.Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapyProdrug and antedrug: two diametrical approaches in designing safer drugs.Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16.Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection modelA review of famciclovir in the management of genital herpes.Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virusIn vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.Antiviral therapy: current concepts and practicesNovel drug delivery approaches on antiviral and antiretroviral agents.2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.New antiviral agents.A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses.Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screeningManagement of genital herpes simplex infection.Helicase-primase as a target of new therapies for herpes simplex virus infections.Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.Synthesis and anti-HCMV activity of novel acyclic nucleosides.Treatment of varicella in the immunocompetent adult.Famciclovir (FAMVIR).Prodrugs of herpes simplex thymidine kinase inhibitors.Liver transplantation for hepatitis B: what have we learned and what does the future hold?Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues.
P2860
Q24672068-B6B1DE92-326B-4A6E-9FCE-2D563ADDEEE8Q24683811-B98CAE44-2381-4C3B-86BC-980E40729FB6Q24797196-65A23FD2-4A31-41B5-B44F-5CD3881C4560Q28293932-286293FD-C728-4C60-B7C0-D5BAE16C20B7Q28327167-815A53DA-8EF3-4F8E-BB6D-1F41F107C92EQ28365198-7A3FABA4-42B9-429B-969E-7ED7372B6711Q28367893-B6596CC5-3076-4073-9E64-4400024ACCDCQ28369279-C0E948A4-B3A9-481A-849F-60DE94709874Q28369457-3A359BD5-36DD-43CC-8D42-74393A9A9E7FQ33801322-255A6E99-F46D-4302-9185-A6911F7B1CFDQ33837094-5BD52660-A75D-4931-A7D1-1BFC929A092DQ33982508-9B8CF989-5A8D-4574-8EBA-1E5AE02CC135Q34027426-2C420E55-AD82-4593-8F6B-76C79C26D859Q34149904-1B1A5143-3C1E-4697-A4E5-8D0DB64545D7Q34270723-BCDE1529-92F3-4C5E-BE86-8DE5B196D91CQ34551831-33165FBB-D3CF-4940-AAE2-5E934B5AB1B3Q34579981-3E3B4715-FE47-4ADE-BF90-AEFA06399DEFQ34636308-9746693C-C50D-4D87-8ED2-F09520319BDBQ34729783-70C330E4-FD5F-4B8D-9FBD-FA871251FF47Q35123563-B9008C8D-6F72-44C5-987E-5768879C7B26Q35615364-0F943852-5D3E-4549-9D02-D855C264EA6EQ35816348-F0CAF6EC-AB1C-4BD5-85CE-86CC94B96325Q35826062-ABE45878-DDE1-4908-BC02-A2285324B6E3Q36070394-7266A43A-B0FE-4413-A3CA-D649AFF9F534Q36283306-4959DC1C-B239-43FA-B79D-9C21B9BDB520Q36364125-FB257FD2-84C7-4754-8391-DF1B3BBB5AA5Q36525651-DDDAA20B-379B-406D-9180-89A969CE3829Q37059841-D63BEEAB-44BB-4C8D-AC27-8BEDA0885E3AQ37252268-F409262C-62CB-4F72-B6C6-47CBD877686EQ37278489-82A0F5FE-E76A-4622-B462-46BA0ED5E441Q37545127-3D380B38-9DAA-4F5C-881D-205A64343A5EQ38351481-6927D586-1A14-4C8A-9B35-03B1BA1F9E45Q39535925-F9FF7E37-B5BE-4C06-B238-6195D45B9A9FQ40055204-541AD083-77DC-4A46-BD6E-BBD7530EA8C9Q40681138-A26995FE-5DC0-4F9F-A9BB-62021313C6B0Q40724561-BDE51ADC-CBA8-4CF6-94EA-45C982EEEAFFQ40907587-FCAD2709-A56A-4AF3-A549-2F786FCF1970Q40954239-2F96FB48-C0F5-4D66-BBEC-3E93A370935FQ40979372-17C1241D-3AFB-4700-B2A0-056270453797Q41401035-589127C5-4096-4F0B-AADD-A9BE51B08466
P2860
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]
description
1989 nî lūn-bûn
@nan
1989 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@ast
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@en
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@nl
type
label
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@ast
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@en
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@nl
prefLabel
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@ast
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@en
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@nl
P2093
P2860
P356
P1476
Selection of an oral prodrug ( ...... but-l-yl)guanine; penciclovir]
@en
P2093
M R Harnden
R A Vere Hodge
R L Jarvest
P2860
P304
P356
10.1128/AAC.33.10.1765
P407
P577
1989-10-01T00:00:00Z